Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA1553 pragmatic randomized placebo-controlled phase 3 trial for chikungunya prevention in Kenya
PACTR202508701657421Phase 3Not yet recruiting
- Sponsor
- Valneva
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Chikungunya (CHIKV) comparing VLA1553 with Placebo (2 arms). Primary endpoint: Occurrence of acute symptomatic virologically confirmed CHIKV infection. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
chikungunya vaccine (live)
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on PACTR202508701657421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202508701657421.